POLE4
POLE4 (DNA polymerase epsilon subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.
Overview
Accessory component of the DNA polymerase epsilon complex. Participates in DNA repair and in chromosomal DNA replication.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Pembrolizumab.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · POLE4 (DNA polymerase epsilon subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.
- 1 · What it is
POLE4 (DNA polymerase epsilon subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.
- 2 · What goes wrong in cancer
Accessory component of the DNA polymerase epsilon complex. Participates in DNA repair and in chromosomal DNA replication.
- 3 · How drugs use it
No product in this corpus aims at POLE4 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:18755 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NR33 (protein name, function text, keywords and locations (REST API)); CIViC gene POLE4 (1 evidence items, 0 assertions, 1 variants; diseases: Lung Adenocarcinoma (GraphQL API, CC0))
Biology
Accessory component of the DNA polymerase epsilon complex. Participates in DNA repair and in chromosomal DNA replication. Location: Nucleus (UniProt). Locus 2p12 (HGNC).
- Non-small-cell lung cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"POLE4" OR ABSTRACT:"POLE4" OR TITLE:"DNA polymerase epsilon 4, accessory subunit" OR ABSTRACT:"DNA polymerase epsilon 4, accessory subunit" OR TITLE:"DNA polymerase epsilon subunit 4" OR ABSTRACT:"DNA polymerase epsilon subunit 4" OR TITLE:"p12" OR ABSTRACT:"p12") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about POLE4, not a curated reading list.